SOUTH CAROLINA – April 1, 2026 – Dxcover is a clinical-stage diagnostics company developing AI-enabled liquid biopsy tests for early cancer detection. Its proprietary platform combines infrared spectroscopy with AI to analyze the full biochemical signature of blood, capturing both tumor and host-response signals. With one of the largest spectral multi-omic datasets globally and the first regulatory approval of its kind, Dxcover is scaling across the UK, EU, and US to deliver accessible, high-throughput cancer diagnostics.
Solutions
Dxcover has developed an AI-enabled liquid biopsy platform to improve early cancer detection by analyzing the full biochemical signature of blood. Its proprietary PANAROMIC™ platform combines infrared spectroscopy with machine learning to capture both tumor-derived and host-response signals, enabling detection where traditional molecular approaches are limited. Supported by one of the largest spectral multi-omic datasets globally and the first regulatory approval of its kind, the platform delivers rapid, low-cost, high-throughput testing within standard laboratory workflows. Dxcover is advancing applications across brain, gynecological and pancreatic cancers to enable earlier diagnosis and improved patient outcomes.
Strengths
- Systemic Biology: Dxcover’s platform analyses the full biochemical signature of blood, capturing both tumor and host-response signals rather than relying solely on tumor-derived DNA.
- Proven Dataset: Dxcover has generated one of the largest spectral multi-omic liquid biopsy datasets globally (~9,000+ patients and 250,000+ samples), underpinning model performance and ongoing product development.
- Regulatory First: Dxcover has achieved the world’s first regulatory approval of a spectral multi-omic liquid biopsy, demonstrating clinical validity and readiness for deployment.
- Scalable Platform: The PANAROMIC™ platform enables rapid, low-cost, high-throughput testing compatible with centralized laboratory workflows, supporting broad population-scale adoption.
Meet the Team

From left to right:
Matthew J. Baker, Ph.D., FRSC | Chief Executive Officer
Holly Butler, Ph.D. | Chief Technology Officer
David Palmer, Ph.D. | Chief Scientific Officer